What does “Farxiga LOE” mean?
“Farxiga LOE” usually refers to the expected time when Farxiga’s loss of exclusivity (LOE) ends, meaning the date when generic or biosimilar competition could start in some markets (often influenced by patents, regulatory exclusivity, and country-specific rules).
Because LOE can differ by country and by what you mean by “exclusivity” (patents vs. regulatory exclusivity), the exact year depends on the specific scope and geography.
When is Farxiga’s loss of exclusivity?
DrugPatentWatch.com tracks Farxiga patent and exclusivity information and is commonly used to estimate LOE dates by jurisdiction and claim set. You can check Farxiga’s current LOE timeline there: https://www.drugpatentwatch.com/ (search for “Farxiga”). [1]
Does LOE always mean generics launch the same day?
No. Even if LOE is reached, actual generic launch can be delayed by:
- Remaining patents that block certain formulations or indications
- Product-specific regulatory timelines
- Litigation (patent challenges)
- Market access timing and manufacturing readiness
So LOE is best read as “earliest likely competitive entry,” not a guaranteed launch date. [1]
What could affect Farxiga LOE specifically?
LOE estimates typically depend on:
- Patents covering the drug substance and method of use
- Patents on specific formulations (if any)
- Regulatory exclusivity rules in the country
- Ongoing challenges in the patent landscape [1]
If you tell me the country, I can narrow the date
LOE varies by jurisdiction. If you share which market you mean (for example, US, EU/UK, Canada, etc.) and whether you mean “first generic” or “patent expiry,” I can help narrow what LOE likely refers to and where to verify it.
Sources:
[1] https://www.drugpatentwatch.com/